Jacobo Rogado1,2, Fernando Pozo3, Kevin Troulé3, José Miguel Sánchez-Torres4,5, Nuria Romero-Laorden4,5, Rebeca Mondejar4,5,6, Olga Donnay4,5, Anabel Ballesteros4,5, Vilma Pacheco-Barcia4,7, Javier Aspa4,8, Fátima Al-Shahrour3, Arantzazu Alfranca4,9, Ramon Colomer4,5,6. 1. Medical Oncology Department, Hospital Universitario Infanta Leonor, Gran via del este 80, 28031, Madrid, Spain. jacobo.rogado@gmail.com. 2. Instituto de Investigación Sanitaria del Hospital Universitario la Princesa, Madrid, Spain. jacobo.rogado@gmail.com. 3. Bioinformatics Unit, Spanish National Cancer Research Centre, Madrid, Spain. 4. Instituto de Investigación Sanitaria del Hospital Universitario la Princesa, Madrid, Spain. 5. Medical Oncology Department, Hospital Universitario la Princesa, Madrid, Spain. 6. Department of Medicine and Chair of Personalized Precision Medicine, Universidad Autónoma de Madrid, Madrid, Spain. 7. Medical Oncology Department, Hospital Central de la Defensa Gómez Ulla, Madrid, Spain. 8. Neumology Department, Hospital Universitario la Princesa, Madrid, Spain. 9. Immunology Department. Hospital, Universitario la Princesa, Madrid, Spain.
Abstract
PURPOSE: Immune checkpoint inhibitors are one of the most effective treatments available in advanced non-small cell lung cancer. However, at present, there are no clinical or analytical biomarkers that define which patients benefit with certainty from these treatments. In our study, we evaluated whether excess weight could be a good predictive biomarker of benefit from these drugs. METHODS: We studied a population of 79 patients, divided into a study group with 39 patients diagnosed with non-small cell lung cancer treated with immunotherapy and 40 patients in a control group, diagnosed with different advanced cancers, treated with non-immunotherapy treatment. We analyzed according to the presence of excess weight or not, the treatment's outcome in the study group and in the control group (objective response, and progression-free and overall survival). RESULTS: In our study, we detected a better response rate to immunotherapy in patients with excess weight (62.50 vs 26.08%, OR 4.72, p = 0.02), and a better median progression-free survival (14.19 vs 5.03 months, HR 0.50, p = 0.058) and median overall survival (33.84 months vs 20.76 months, HR 0.43, p = 0.01) in the study group. These findings were specific to the immunotherapy group since in the control group, with patients who did not receive immune checkpoint inhibitors, these findings were not found. CONCLUSION: Our study suggests that patients with excess weight who receive anti-PD-1 immune checkpoint inhibitors diagnosed with non-small cell lung cancer have a better outcome. This effect is specific to patients receiving immunotherapy.
PURPOSE: Immune checkpoint inhibitors are one of the most effective treatments available in advanced non-small cell lung cancer. However, at present, there are no clinical or analytical biomarkers that define which patients benefit with certainty from these treatments. In our study, we evaluated whether excess weight could be a good predictive biomarker of benefit from these drugs. METHODS: We studied a population of 79 patients, divided into a study group with 39 patients diagnosed with non-small cell lung cancer treated with immunotherapy and 40 patients in a control group, diagnosed with different advanced cancers, treated with non-immunotherapy treatment. We analyzed according to the presence of excess weight or not, the treatment's outcome in the study group and in the control group (objective response, and progression-free and overall survival). RESULTS: In our study, we detected a better response rate to immunotherapy in patients with excess weight (62.50 vs 26.08%, OR 4.72, p = 0.02), and a better median progression-free survival (14.19 vs 5.03 months, HR 0.50, p = 0.058) and median overall survival (33.84 months vs 20.76 months, HR 0.43, p = 0.01) in the study group. These findings were specific to the immunotherapy group since in the control group, with patients who did not receive immune checkpoint inhibitors, these findings were not found. CONCLUSION: Our study suggests that patients with excess weight who receive anti-PD-1 immune checkpoint inhibitors diagnosed with non-small cell lung cancer have a better outcome. This effect is specific to patients receiving immunotherapy.
Authors: Vincent K Lam; Søren M Bentzen; Pranshu Mohindra; Elizabeth M Nichols; Neha Bhooshan; Melissa Vyfhuis; Katherine A Scilla; Steven J Feigenberg; Martin J Edelman; Josephine L Feliciano Journal: Lung Cancer Date: 2016-12-01 Impact factor: 5.705
Authors: Suzanne E Dahlberg; Joan H Schiller; Philip B Bonomi; Alan B Sandler; Julie R Brahmer; Suresh S Ramalingam; David H Johnson Journal: J Thorac Oncol Date: 2013-09 Impact factor: 15.609
Authors: Béatrice Lauby-Secretan; Chiara Scoccianti; Dana Loomis; Yann Grosse; Franca Bianchini; Kurt Straif Journal: N Engl J Med Date: 2016-08-25 Impact factor: 91.245
Authors: Christine L Parr; G David Batty; Tai Hing Lam; Federica Barzi; Xianghua Fang; Suzanne C Ho; Sun Ha Jee; Alireza Ansary-Moghaddam; Konrad Jamrozik; Hirotsugu Ueshima; Mark Woodward; Rachel R Huxley Journal: Lancet Oncol Date: 2010-06-30 Impact factor: 41.316